Daiichi Sankyo has integrated its Japanese supply chain subsidiaries, Daiichi Sankyo Propharma (DSPP) and Daiichi Sankyo Chemical Pharma (DSCP) Odawara plants.
Subscribe to our email newsletter
The integration aims to build a consistent system of manufacturing everything from intermediates to API while utilizing scientific research capabilities to enhance the manufacturing technology infrastructure and make Daiichi Sankyo structurally competitive on a global level.
As part of the integration, the DSPP Odawara plant has been split off and absorbed into DSCP, which will act as the succeeding company through an Absorption-type Company Split as provided for in "The Companies Act of Japan."
The new plant, Daiichi Sankyo Chemical Pharma will spread across 133,000 m2 and manufacture API and intermediates for pharmaceuticals (olmesartan medoxomil, loxoprofen sodium, etc.)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.